Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details) - Schedule of deferred tax assets

v3.22.4
Income Taxes (Details) - Schedule of deferred tax assets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current:    
Accrued expenses $ 133,591 $ 144,077
Stock compensation 354,274 1,800,762
Net operating loss carryforward 20,980,803 19,481,137
Research and development credit carry forward 1,340,317 252,536
Capitalized research and development 1,419,818
Total deferred tax assets 24,228,803 21,678,512
Valuation allowance (24,228,803) (21,678,512)
Deferred tax asset, net of valuation allowance